Shares of RPG Life Sciences fell sharply by over 10% in early morning trade today after the company reported a weak set of Q3 financial results, with a sharp decline in profitability despite modest revenue growth. The stock came under heavy selling pressure as investors reacted to lower margins and earnings.
During the session, RPG Life Sciences shares touched a day’s low of ₹1,890.00 and a high of ₹2,040.00, compared with the previous close of ₹2,102.20. The stock opened at ₹1,995.90 and remains close to its 52-week low of ₹1,835.00, significantly below the 52-week high of ₹2,725.00.
In the December quarter, RPG Life Sciences reported a net profit of ₹22.1 crore, marking a sharp decline of 36.7% year-on-year from ₹34.9 crore in the corresponding quarter last year. Revenue for the quarter stood at ₹180 crore, up 4.2% year-on-year from ₹172.7 crore.
EBITDA declined 19.5% year-on-year to ₹39.5 crore, compared with ₹49 crore in the same quarter last year. As a result, EBITDA margin contracted sharply to 21.9% from 28.4% on a year-on-year basis.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
